3 completed, 1 not yet recruiting, 1 unknown. 5 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 3, Not yet recruiting 1, Unknown 1 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
Follow Colorectal Adenoma: new trials by email Literature Review of Colorectal Adenoma trials Research Report on Colorectal Adenoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Jianpi Lishi Jiedu Granules for Prevention of Postoperative Recurrence in Colorectal Advanced Adenomas Jianpi Lishi Jiedu Granules, Placebo granules - Colorectal Adenoma | Phase 3 | Not yet recruiting | Nanjing First Hospital, Nanjing Medical University | 376 | 2026-05-01 | 2026-04-01 |
| Study of Berberine Hydrochloride in Prevention of Colorectal Adenomas Recurrence Berberine hydrochloride, placebo - Colorectal Adenoma | Phase 2 / Phase 3 | Completed | Shanghai Jiao Tong University School of Medicine | 1108 | 2014-11-01 | 2019-03-26 |
| Study of Calcium Plus Vitamin D Supplementation in Prevention of Colorectal Adenomas Recurrence Ca plus vit D - Colorectal Adenoma | Phase 2 / Phase 3 | Unknown | Shanghai Jiao Tong University School of Medicine | 900 | 2014-03-01 | 2014-05-21 |
| Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP) Celecoxib - Colorectal Adenoma | Phase 3 | Completed | Pfizer | 1561 | 2001-02-01 | 2008-08-06 |
| A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122) MK0966; Rofecoxib / Duration of Treatment: 156 weeks, Placebo/ Duration of Treatment: 156 weeks - Colorectal Adenoma | Phase 3 | Completed | Merck Sharp & Dohme LLC | 2586 | 1999-12-23 | 2017-05-09 |
Calcium Carbonate (1) · Celecoxib (1) · Duration of Therapy (1) · rofecoxib (1)
Shanghai Jiao Tong University School of Medicine (2) · Merck Sharp & Dohme LLC (1) · Nanjing First Hospital, Nanjing Medical University (1) · Pfizer (1)
China (3) · Australia (1) · Belgium (1) · Brazil (1) · Canada (1) · Chile (1) · Czechia (1) · Denmark (1) · Finland (1) · France (1) · Germany (1) · Hong Kong (1) · Hungary (1) · Ireland (1) · Israel (1)
Jing-Yuan Fang, M.D., Ph.D (2)
PMID 16943394, PMID 16943401, PMID 18378608, PMID 18922570, PMID 21503000, PMID 22386831, PMID 31926918, PMID 37553874